Fig. 3From: HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world studySurvival outcomes of patients with different high-risk factors. (a), (b) and (c) were the PFS of patients with Vp4, TO ≥ 50% and both respectively. (d), (e) and (f) were the OS of patients with Vp4, TO ≥ 50% and both respectivelyBack to article page